Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AE Sphingosine-1-phosphate (S1P) receptor modulators
L04AE02 Ozanimod
D10967 Ozanimod hydrochloride (JAN/USAN) <US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Multiple Sclerosis Agents
Ozanimod
D10967 Ozanimod hydrochloride (JAN/USAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Sphingolipid
S1PR
D10967 Ozanimod hydrochloride (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10967
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10967
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10967